Skip to main content
. 2021 Jan 12;40(8):3053–3065. doi: 10.1007/s10067-020-05545-y

Fig. 4.

Fig. 4

The safety evaluation of IL-17A inhibitors in AS. Forest plots of ORs for AEs (A), SAEs (B), nasopharyngitis (C), DDAAEs (D), infections (E), and serious infections